Zachary Michael Corey

Dr. Zachary Michael Corey

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2025 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
CJCyril Jacquot
Cyril Jacquot
MMMaria Di Mola
Maria Di Mola
RJReuben Jacob
Reuben Jacob
GMGagan Mathur
Gagan Mathur
CPCheryl Pacheco
Cheryl Pacheco
KAKyle Annen
Kyle Annen

22 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
KKKarshana Jagathi Kalyanaraman
Karshana Jagathi Kalyanaraman
ZCZachary Michael Corey
Zachary Michael Corey
ANAndre Navarro
Andre Navarro
LHLynn E Heasley
Lynn E Heasley
RNRaphael A. A Nemenoff
Raphael A. A Nemenoff
The application of personalized medicine to lung adenocarcinoma has resulted in new therapies based on specific oncogenic drivers that have improved patient outcomes. However, oncogene-defined subsets of patients exhibit a significant heterogeneity of response to these agents. Defining the factors that mediate the varied depth and duration of response are critical to developing new therapeutic strategies. While the examination of patient samples can provide important correlations, definitive mechanistic studies require the use of relevant preclinical models. Based on a large body of data, interactions between cancer cells and the surrounding tumor microenvironment, comprised of inflammatory, immune, and vascular cells, represent a critical determinant of therapeutic response. In this review, we focus on preclinical models that can be used to explore these interactions, identify new therapeutic targets, and test combination therapies. In particular, we will describe the use of implantable orthotopic immunocompetent models employing a panel of murine lung adenocarcinoma cell lines with oncogenic drivers common to human lung adenocarcinoma as a powerful system to develop new treatment approaches.

1 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ZCZachary Michael Corey
Zachary Michael Corey
ARAisha Rashid
Aisha Rashid
KSKreesha Shah
Kreesha Shah
BABillal Alamarie
Billal Alamarie
Joseph Y. ClarkJoseph Y. Clark
Joseph Y. Clark
Background/Objectives: To test the accuracy of two sound-based voided volume measurement applications compared to voided volume based on the measurement of pre- and post-void weight using a high-resolution scale. Methods: Seven male and four female volunteers participated. Male and female volunteers used the ProudP and Healthy Bladder-Voiding Diary mobile apps, respectively, to measure sound-based voided volume (SVV). The difference between pre- and post-void weight was calculated and converted to mL to be the true-voided volume (TVV) using a high-resolution scale. A Pearson correlation coefficient and paired t-test were completed. Results: Eighty-two voids were recorded (42M/40F). Median male participant age was 25.9 years. Male SVV ranged from 42-790 mL and TVV ranged from 61-880 mL. Mean difference was 39 mL (95% CI, 18-59 mL). SVV and TVV comparison revealed a strong correlation (r = 0.977, p < 0.0001). Equivalence testing indicated a p-value of 0.022. Median female participant age was 25.0 years. Female SVV ranged from 28-440 mL and TVV ranged from 10-682 mL. Mean difference was 53 mL (95% CI, 22-84 mL). Equivalence testing indicated a p-value of 0.330. SVV and TVV comparison revealed a correlation (r = 0.888, p < 0.0001). Conclusions: The male and female app have a strong correlation to true void volume (male > female app) and can be used by patients to track voided volume at home. The male app accurately measures voided volume within 60 mL from the TVV; however, the female app is less accurate.

30 September 2026 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
ZCZachary Michael Corey
Zachary Michael Corey
MJMckinzie Johnson
Mckinzie Johnson
JFJohn Fowler
John Fowler
JWJoshua Wisell
Joshua Wisell
DADara L. Aisner
Dara L. Aisner
SRShyam Raghavan
Shyam Raghavan

4 March 2026 in The American Journal of Dermatopathology
Verified
Journal Article
Closed access
ZCZachary Michael Corey
Zachary Michael Corey
DWDanica Wiredja
Danica Wiredja
NWNicholas Do Willard
Nicholas Do Willard
JWJoshua Wisell
Joshua Wisell
SRShyam S. Raghavan
Shyam S. Raghavan
Spitz neoplasms comprise a spectrum of melanocytic lesions with overlapping clinical and histologic features. BRAF fusions account for only 5%–6% of Spitz neoplasms with a limited number of fusion partners being characterized. We report 2 Spitz nevi with novel BRAF fusions and reproducible morphologic findings. The first case, a 35-year-old man with a finger mass, morphologically demonstrated intraepidermal and dermal proliferation of enlarged epithelioid melanocytes without maturation, and a striking pattern of neurotropism and angiotropism. Immunohistochemistry revealed <30% PRAME expression and retained p16, while next-generation sequencing identified a novel in-frame AHNAK::BRAF fusion. The second case, a 47-year-old man with an atypical skin lesion on the back of his neck, exhibited a circumscribed intradermal proliferation of epithelioid and spindle melanocytes with Spitzoid cytomorphology, again characterized by the striking pattern of neurotropism and entrapment of epithelioid cells within a fibrous stroma. This lesion was PRAME-negative with retained p16, and molecular studies identified a novel PDE4DIP::BRAF fusion. Both fusions preserved the BRAF kinase domain while eliminating its N-terminal regulatory regions. These cases expand the molecular spectrum of Spitz neoplasms and underscore neurotropism as a potential morphologic clue for BRAF fusion-driven Spitz nevi.

16 January 2025 in Dermatopathology
Verified
Journal Article
Open access
PDF file
ZCZachary Michael Corey
Zachary Michael Corey
LLLydia An Luu
Lydia An Luu
SNSabrina A. Newman
Sabrina A. Newman
SRShyam Raghavan
Shyam Raghavan
We present the case of a 60-year-old immunocompromised man who presented with two pruritic pink–red indurated nodules with overlying scale and focal areas of ulceration on his left dorsal and left medial forearm, which evolved over a 2-month period. The pathology showed numerous fungal hyphae present that were pauci-septate with various branched angles and variable hyphal thickness. Fungal cultures grew Rhizopus species and a universal fungal PCR detected the Rhizopus oryzae complex. Based on the clinicopathologic correlation, the diagnosis of cutaneous mucormycosis was made. Cutaneous mucormycosis is an aggressive fungal infection of the Mucorales family occurring after the inoculation of fungal spores in disrupted skin. It usually presents as a necrotic eschar but can also present as cellulitis that evolves into a necrotic ulcer. A prompt diagnosis is critical for the effective management of cutaneous mucormycosis. The treatment includes an immediate systemic treatment with amphotericin B and a surgical debridement of the necrotic regions. Given the wide range of presenting symptoms, clinical suspicion for this emergent condition must remain high in immunocompromised and diabetic patients.